Pichini Amanda, Ahmed Arzoo, Patch Christine, Bick David, Leblond Mathilde, Kasperaviciute Dalia, Deen Dasha, Wilde Simon, Garcia Noriega Sofia, Matoko Christella, Tuff-Lacey Alice, Wigley Chris, Scott Richard H
Genomics England, London, United Kingdom.
Engagement and Society, Wellcome Connecting Science, Wellcome Genome Campus, Hinxton, United Kingdom.
Front Genet. 2022 May 30;13:866168. doi: 10.3389/fgene.2022.866168. eCollection 2022.
The transformative potential of whole genome sequencing (WGS) as a diagnostic tool in healthcare has been demonstrated by initiatives including the 100,000 Genomes Project and is now offered to certain patients in the National Health Service (NHS) in England. Building on these foundations, the utility of WGS in the newborn period can now be explored. Genomics England is working in partnership with NHS England and NHS Improvement and other healthcare, patient and public interest groups to design a research program embedded in the NHS to explore the potential challenges and implications of offering WGS in all newborns. The program will aim to: 1) evaluate the feasibility, utility and impact on the NHS of screening for childhood-onset rare actionable genetic conditions; 2) understand how, with consent, genomic and healthcare data could be used to enable research to develop new diagnostics and treatments; and 3) explore the implications of storing an individual's genome for use over their lifetime. Recognizing the important practical, scientific and ethical questions that we must explore in dialogue with the public and experts, we are taking a collaborative, evidence-based and ethically deliberate approach to designing the program. An iterative co-design process including a nationwide public dialogue has identified emergent themes and ethical considerations which are the focus of the program's design. These themes will be further developed through continued engagement with healthcare professionals, researchers, ethics experts, patient groups and the public, with an ongoing commitment to embedding ongoing ethics research and co-design into the delivery of the program.
全基因组测序(WGS)作为医疗保健领域诊断工具的变革潜力已在包括“10万基因组计划”等项目中得到证明,目前英格兰国民医疗服务体系(NHS)已向部分患者提供该技术。在此基础上,现在可以探索WGS在新生儿期的应用价值。英国基因组学公司正与英国NHS、NHS改进部门以及其他医疗保健、患者和公共利益团体合作,设计一个嵌入NHS的研究项目,以探索对所有新生儿提供WGS的潜在挑战和影响。该项目旨在:1)评估筛查儿童期罕见可干预遗传疾病对NHS的可行性、实用性和影响;2)了解在获得同意的情况下,基因组和医疗数据如何能够用于推动研发新的诊断方法和治疗手段的研究;3)探讨存储个人基因组以供其一生使用的影响。认识到我们必须与公众和专家进行对话,探讨重要的实践、科学和伦理问题,我们正在采取合作、基于证据且符合伦理的审慎方法来设计该项目。一个包括全国范围公众对话的迭代式共同设计过程已经确定了一些新出现的主题和伦理考量因素,这些是该项目设计的重点。通过与医疗保健专业人员、研究人员、伦理专家、患者团体和公众持续互动,这些主题将得到进一步发展,并持续致力于将正在进行的伦理研究和共同设计融入项目实施过程中。